We conclude that treatment decisions in managing both radiographic and non-radiographic AxSpA should be based on shared decision-making with patients, the clinical effectiveness of drug class, co-morbidity and cost. At present, we have limited head-to-head data to prioritize one drug class over another for first-line treatment but can recommend tumor necrosis factor (TNF), interleukin 17 (IL17) and JAK inhibition as being comparable in terms of clinical, structural and patient-reported outcome measures. Further real-world data may guide treatment decision-making in individual patients.
Keyphrases
- patient reported
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- randomized controlled trial
- systematic review
- prognostic factors
- systemic lupus erythematosus
- emergency department
- disease activity
- replacement therapy
- combination therapy
- artificial intelligence